Literature DB >> 17568814

Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution.

A K Stewart, H Chang, S Trudel, K C Anderson, P Richardson, M Alsina, D Reece, S Young, A Sable-Hunt, Z Li, J Keats, S Van Wier, G Ahmann, T Price-Troska, K Giusti, P L Bergsagel, M Chesi, R Fonseca.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17568814      PMCID： PMC3882151          DOI： 10.1038/sj.leu.2404800

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  R Fonseca; M M Oken; P R Greipp
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

2.  Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma.

Authors:  Hong Chang; A Keith Stewart; Xiao Ying Qi; Zhi Hua Li; Qi Long Yi; Suzanne Trudel
Journal:  Blood       Date:  2005-03-10       Impact factor: 22.113

3.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

4.  Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.

Authors:  M O Chandesris; J Soulier; S Labaume; A Crinquette; L Repellini; K Chemin; M Malphettes; C Fieschi; B Asli; Y Uzunhan; J P Fermand; J C Bories; B Arnulf
Journal:  Br J Haematol       Date:  2007-02       Impact factor: 6.998

5.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Authors:  Hervé Avet-Loiseau; Michel Attal; Philippe Moreau; Catherine Charbonnel; Frédéric Garban; Cyrille Hulin; Serge Leyvraz; Mauricette Michallet; Ibrahim Yakoub-Agha; Laurent Garderet; Gérald Marit; Lucienne Michaux; Laurent Voillat; Marc Renaud; Bernard Grosbois; Gaelle Guillerm; Lotfi Benboubker; Mathieu Monconduit; Catherine Thieblemont; Philippe Casassus; Denis Caillot; Anne-Marie Stoppa; Jean-Jacques Sotto; Marc Wetterwald; Charles Dumontet; Jean-Gabriel Fuzibet; Isabelle Azais; Véronique Dorvaux; Marc Zandecki; Régis Bataille; Stéphane Minvielle; Jean-Luc Harousseau; Thierry Facon; Claire Mathiot
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

6.  CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

Authors:  Suzanne Trudel; Zhi Hua Li; Ellen Wei; Marion Wiesmann; Hong Chang; Christine Chen; Donna Reece; Carla Heise; A Keith Stewart
Journal:  Blood       Date:  2004-12-14       Impact factor: 22.113

7.  Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.

Authors:  Jonathan J Keats; Christopher A Maxwell; Brian J Taylor; Michael J Hendzel; Marta Chesi; P Leif Bergsagel; Loree M Larratt; Michael J Mant; Tony Reiman; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

8.  The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.

Authors:  Hong Chang; Stephen Sloan; Dan Li; Lihua Zhuang; Qi-Long Yi; Christine I Chen; Donna Reece; Kathy Chun; A Keith Stewart
Journal:  Br J Haematol       Date:  2004-04       Impact factor: 6.998
  8 in total
  7 in total

Review 1.  Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.

Authors:  Lesley J Scott; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

Review 2.  Latest advances and current challenges in the treatment of multiple myeloma.

Authors:  Anuj Mahindra; Jacob Laubach; Noopur Raje; Nikhil Munshi; Paul G Richardson; Kenneth Anderson
Journal:  Nat Rev Clin Oncol       Date:  2012-02-21       Impact factor: 66.675

3.  Clonal competition with alternating dominance in multiple myeloma.

Authors:  Jonathan J Keats; Marta Chesi; Jan B Egan; Victoria M Garbitt; Stephen E Palmer; Esteban Braggio; Scott Van Wier; Patrick R Blackburn; Angela S Baker; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John D Carpten; Michael Barrett; Rafael Fonseca; A Keith Stewart; P Leif Bergsagel
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

4.  Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.

Authors:  Efstathios Kastritis; Maria Roussou; Maria Gavriatopoulou; Nikolaos Kanellias; Magdalini Migkou; Evangelos Eleutherakis-Papaiakovou; Dimitrios C Ziogas; Despina Fotiou; Ioannis Ntanasis-Stathopoulos; Ioanna Dialoupi; Stavroula Giannouli; Panagiotis Tsirigotis; Sossana Delimpasi; Despina Mparmparousi; Mairylin Spyropoulou-Vlachou; Aikaterini Xirokosta; Evangelos Terpos; Meletios A Dimopoulos
Journal:  Blood Adv       Date:  2019-12-10

Review 5.  Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.

Authors:  He Huang; Heng-Wei Wu; Yong-Xian Hu
Journal:  J Zhejiang Univ Sci B       Date:  2020 Jan.       Impact factor: 3.066

Review 6.  Management of double-refractory multiple myeloma.

Authors:  Jason P Meadows; Tomer M Mark
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 7.  Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.

Authors:  Wen-Chi Yang; Sheng-Fung Lin
Journal:  Biomed Res Int       Date:  2015-11-16       Impact factor: 3.411
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.